Oncocytic tumours of the salivary gland, kidney, and thyroid: nuclear DNA patterns studied by flow cytometry. by Rainwater, L. M. et al.
Br. J. Cancer (1986), 53, 799-804
Oncocytic tumours of the salivary gland, kidney, and
thyroid: Nuclear DNA patterns studied by flow cytometry
L.M. Rainwater', G.M. Farrow2, I.D. Hay3 & M.M. Lieber'
Departments of 1Urology and 2Pathology, 3Division ofEndocrinology and Internal Medicine, Mayo Clinic and
Mayo Foundation, Rochester, Minnesota 55905 USA.
Summary Nuclear DNA ploidy studies were performed by flow cytometry on extracted nuclei from 12
oncocytic tumours of the salivary gland, 65 oncocytic tumours of the kidney, and 37 oncocytic tumours of the
thyroid gland from the pathology archives of the Mayo Clinic. In order to provide an interesting clinical
spectrum, three different classes of well-differentiated oncocytic tumours were selected for examination.
Salivary gland oncocytic tumours were chosen for their generally benign behaviour. Oncocytic thyroid cancers
exhibiting malignant potential because of local invasion, were thought to represent the opposite extreme of
aggressiveness. Renal oncocytic tumours were known to demonstrate an intermediate degree of malignancy.
All of the oncocytic salivary gland tumours showed a 'normal' DNA histogram and had a benign clinical
course. For the oncocytic tumours of the kidney, 45% of DNA histograms were normal, 40% exhibited a
significant increase in the DNA tetraploid/polyploid (4C) peak, and 15% showed a DNA aneuploid peak.
Three patients with a DNA tetraploid pattern developed tumour metastasis and two have died from
metastatic renal cancer. Among the oncocytic thyroid cancers, 27% were normal, 22% exhibited an increased
DNA tetraploid peak, and 51% had a distinct DNA aneuploid peak. None of the thyroid tumour patients
with a normal DNA pattern or with an increased DNA tetraploid peak died as a result of thyroid
malignancy. In contrast, 58% of patients whose thyroid tumours showed a DNA aneuploid peak
subsequently died from thyroid cancer.
Oncocyte is a term that has been used to describe
large epithelial cells which contain finely granular,
eosinophilic cytoplasm (Hamperl, 1931). These
eosinophilic or oxyphilic granules have been shown
to represent densely packed mitochondria within
the cytoplasm (Eble & Hull, 1984). Oncocytoma is
a term used to describe benign and malignant
neoplasms composed of oncocytes (Hamperl, 1962).
Such oncocytomas or oncocytic tumours have been
identified in the pituitary gland, salivary glands,
thyroid, parathyroid, pancreas, adrenal cortex and
kidney (Hamperl, 1964). Although oncocytomas or
oncocytic tumours of different organs often appear
similar or identical by light microscopy, the
biologic behaviour of oncocytic tumours can vary
significantly. Well differentiated oncocytic tumours
arising from the salivary glands and kidney, in
general, do not metastasize (Gray et al., 1976; Klein
& Valensi, 1976; Lieber et al., 1981). However,
oncocytic or oxyphilic tumours of the thyroid
(known as Hiirthle cell tumours in the USA) are
recognized as having the potential to recur locally,
metastasize, and cause death (Watson et al., 1984).
Although all of these tumour types are relatively
rare, the recent description of a methodology
allowing flow cytometric studies to be performed
on nuclei extracted from paraffin-embedded blocks
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of archival pathology samples (Hedley et al.,
1983,1985) has enabled us to retrospectively study
samples of oncocytic tumours of the salivary
glands, kidney, and thyroid treated at the Mayo
Clinic over more than 30 years. The results of
DNA ploidy measurements of these oncocytic
tumours are presented herein.
Materials and methods
Paraffin-embedded archival material from 72 renal,
37 thyroid and 12 salivary gland oncocytic tumours
were available for laboratory evaluation by flow
cytometry. Haematoxylin and eosin stained slides of
these paraffin-embedded tumour blocks were
reviewed by the study pathologist (GMF) to assess
the correct histologic diagnosis. Twenty-four
different specimens of normal renal parenchyma,
hydronephrosis and pyelonephritis were used as
non-tumour controls. In addition, 30 different
specimens of normal thyroid parenchyma and
diffuse parenchymal hypertrophy were used as non-
tumour controls. Preparation of nuclear suspen-
sions from paraffin-embedded tissue blocks was
carried out using the Hedley technique (Hedley et
al., 1983). Three 30 um thick sections were cut
using a standard tissue microtome. The sections
were placed in 10ml glass culture tubes and
dewaxed using two changes of Histo-Clears
(National Diagnostics, Somerville NJ), 3ml for
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Omin at room temperature, and rehydrated in a
sequence of 3ml of 100%, 95%, 70%, and 50%
ethanol for Omin at room temperature. The tissue
was then washed twice in distilled water and resus-
pended in 1 ml of 0.5% pepsin (P-7012 Sigma), in
0.9% sodium chloride adjusted to pH 1.5. The
specimens were incubated at 37°C for 30min with
frequent intermittent vortex mixing.
The isolated nuclei were stained with propidium
iodide using the method of Vindel0v et al. (1983):
1.8ml of a solution ('A') containing trypsin
0.015gm (T-0134 Sigma) dissolved in 500ml of
stock solution [trisodium citrate, 2g; Nonidet P-40,
2ml, (N-6507 Sigma); spermine tetrahydrochloride,
1.044g, (S-2876 Sigma); Tris(hydroxymethyl)-
aminomethane, 0.121 g, (T-1378 Sigma)] adjusted
to pH 7.6, was added to 0.2ml of cell suspension
in citrate buffer and mixed gently for 10min. Then
1.5ml of a solution ('B') containing trypsin inhibitor
0.25g (T-9253 Sigma) and ribonuclease A 0.05g
(R-4875 Sigma) dissolved in 500ml ofstock solution
adjusted to pH 7.6, was added and mixed gently
for Omin. Finally, 1.5ml of a solution ('C') con-
taining propidium iodide 0.208g, (P-5264 Sigma)
and spermine tetrahydrochloride 0.580g dissolved
in 500ml of stock solution adjusted to pH 7.6, was
added. The solution of propidium iodide was
protected against light with tinfoil during
preparation, storage, and the staining procedure.
The solutions were mixed and the sample was
filtered through a 30pm pore diameter nylon mesh
filter to eliminate nuclear clumps. Samples were run
on the flow cytometer within 30 minutes after the
addition of propidium iodide.
Cellular DNA content was measured on a FACS
IV Flow Cytometer (Becton Dickinson, Sunnyvale,
CA) equipped with a 5 Watt argon ion laser run at
a wavelength of 514nm. Each group of specimens
was standardized with 'Fullbright Fluorospheres'
(Coulter Corp., Hialeah, FL, USA), set to channel
40 on the FACS, in order to control day-to-day
channel variations. Histograms of 20,000 cells were
recorded for each specimen at a maximum
scanning flow rate of 1,000 cells sec-1. In general,
paraffin-embedded nuclear specimens displayed a
relative fluorescence of 55-80% compared to nuclei
from fresh tissue. Nuclear specimen fluorescence
intensities of <40% seen for fresh nuclei for the
DNA diploid (2C) peak were considered non-
evaluable and omitted from analysis. Seven renal
oncocytic tumour specimens were considered non-
evaluable because of low intensity staining. All
oncocytic thyroid tumours and oncocytic salivary
tumour samples were evaluable. Cell cycle
evaluation of the DNA histogram and the
coefficient of variation of the GO/GI peak derived
by flow cytometry was obtained using a computer
program for Dean and Jett mathematical analysis
(Dean & Jett, 1974). Statistical comparison of flow
cytometric data was carried out using the adjusted
chi-square test. Statistical comparison of size for
thyroid tumours was performed with the Student's
t-test.
Tumour DNA content was classified as 'DNA
aneuploid' if a separate peak (GO/GI) was present
different from the 'standard' large DNA diploid
GO/GI (2C) peak and small G2 (4C) peak. The
term 'DNA aneuploidy' by convention is used to
designate an abnormal DNA stemline of cells, but
the absence of an abnormal DNA stemline by flow
cytometry does not exclude the existence of an
abnormal karyotype, such as a balanced trans-
location (Hiddemann et al., 1984). A DNA index
was calculated as a ratio of the peak channel of the
abnormal DNA stemline of cells to the peak
channel of the DNA normal cells. By definition, the
DNA index of normal DNA diploid cells is 1.0
(Barlogie et al., 1978). The 'Fullbright Fluoro-
sphere' singlet peak was always set at channel 40,
while the 'Fullbright Fluorosphere' doublet peak
appeared at channel 85, giving a ratio of 2.125 for
doublet to singlet peaks on the FACS IV
instrument used. All tissue blocks were analyzed
and DNA histograms were assigned as DNA
normal, DNA tetraploid/polyploid, or DNA
aneuploid without knowledge ofpatient survival.
To quantitate the number of nuclei normally
found in the non-tumour 4C or G2 peak, a number
of control renal tissues were studied. Nuclei
extracted from nine formalin fixed and paraffin-
embedded samples of normal human kidney
parenchyma showed mean percent of nuclei in the
4C peak of 5.52+2.46%. For 15 non-tumour
pathologic samples of human hydronephrosis and
human pyelonephritis in which tissues were fixed
and paraffin-embedded, the mean percentage of
nuclei in the 4C peak was 5.86+2.42%. These
control data provide a reasonable basis for using
'>10% of nuclei in the 4C peak' as a criterion for
the classification of 'DNA tetraploid/polyploid' for
the oncocytic renal tumour specimens. The mean
coefficient of variation of the GO/GI peak was
7.78+0.64% for paraffin-embedded samples of
normal human kidney and non-tumour pathologic
samples.
For six formalin fixed and paraffin-embedded
samples of normal human thyroid parenchyma,
mean percent of nuclei in the 4C peak was
6.55+2.09%. For 24 non-tumour thyroid control
tissue samples of thyroid parenchymal hypertrophy
in which cells were fixed and paraffin embedded,
the mean percentage of cells in the 4C peak was
7.77+1.32%. These control data provide a
reasonable basis for using '>10% of nuclei in theFLOW CYTOMETRY OF ONCOCYTIC TUMOURS
4C peak' as a criterion for the classification of
'DNA tetraploid/polyploid' for oncocytic thyroid
cancer specimens. The mean coefficient of variation
of the GO/GI peak was 7.41+0.60% for paraffin-
embedded samples of normal human thyroid and
non-tumour pathologic samples.
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Results
Salivary gland
All 12 (100%) of the salivary gland oncocytoma
tumour samples analyzed exhibited a 'normal'
pattern such as seen in non-tumour control tissues
(Table I). The mean coefficient of variation of the
GO/GI peak was 8.38+1.07% with a range from
6.94 to 9.82%. There was no evidence of DNA
aneuploid or DNA tetraploid (4C) peaks in these
samples. None of the 12 patients with salivary
gland oncocytomas evaluated showed clinical
evidence of recurrence or metastasis when followed
for a median period of five years (range 1-15) after
diagnosis.
Kidney
Seventy-two paraffin-embedded samples of pure
well differentiated oncocytic renal tumours were
available for processing and analysis by flow
cytometry. Of the 72 available oncocytic renal
tumour tissue blocks, 65 (90%) were in fact
evaluable by this method yielding high quality
DNA histograms with high intensity staining
(Table I). The mean coefficient of variation of the
GO/GI peak was 9.61 + 1.76 with a range from 6.49
to 12.89%. Twenty-nine (45%) renal oncocytic
tumours among the evaluable specimens showed
DNA histograms that resembled the DNA
histograms observed for non-tumour control
samples of normal adult human renal parenchyma,
hydronephrosis, and pyelonephritis (Figure 1).
Forty percent (n=26) of evaluable oncocytic
renal tumour specimens showed a substantial to
marked increase (> 10% of nuclei) in the 4C (DNA
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Figure 1 Example of a typical 'normal' DNA
histogram obtained from deparaffinized oncocytic
tumour specimens by flow cytometry.
tetraploid) peak (Figure 2). For the 26 oncocytic
renal tumours placed in the DNA tetra-
ploid/polyploid category, the proportion of nuclei
in the 4C (DNA tetraploid) peak ranged from 10.04
to 58.03% (mean+s.d. 19.9+12.6%). Fourteen
(54%) of the DNA tetraploid/polyploid renal
tumours had more than 15% of nuclei in the 4C
Vak (Figure 2). DNA indices for the polyploid
'cocytic renal tumours varied from 1.98 to 2.28
with a mean DNA index of 2.07+0.07.
In addition, 15% (n= 10) of oncocytic renal
tumours showed a distinct DNA aneuploid peak
(Figure 3). DNA indices for oncocytic renal
tumours with DNA aneuploid histograms varied
from 1.22 to 1.78 with a mean of 1.47+0.20.
Among the 65 oncocytic renal tumour patients
followed for a minimum of five years, three patients
with DNA tetraploid/polyploid patterns developed
Table I Flow cytometry ofoncocytic tumours
DNA histogram pattern
DNA tetraploid DNA aneuploid
Organ oforigin 'Normal' Increased (4C) peak Peak present Total
Salivary gland 12 (100%) 12
Kidney 29 (45%) 26 (40%) 10 (15%) 65
Thyroid 10 (27%) 8 (22%) 19 (51%) 37
Total 51 (45%) 34 (30%) 29 (25%) 114
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flow cytometry (Table I). The mean coefficient of
variation of the GO/GI peaks was 10.50+1.70%
with a range from 7.22 to 13.02%. Ten tumours
(27%) showed DNA histograms that resembled
those observed for non-tumour control samples
(Figure 1). In addition, 22% (n=8) of oncocytic
thyroid cancers showed a significant increase
(> 10% of nuclei) in the 4C (DNA tetraploid) peak
(Figure 2). DNA indices for the oncocytic thyroid
cancers with DNA tetraploid/polyploid histograms
varied from 1.97 to 2.32 with a mean of 2.13+0.12.
Fifty-one percent (n= 19) of oncocytic thyroid
cancers showed an easily identifiable DNA
aneuploid peak (Figure 3). DNA indices for these
19 DNA aneuploid specimens varied from 1.20 to
1.80 with a mean of 1.49+0.19.
For the oncocytic cancer cases studied, excellent
correlation was found between the measured
nuclear DNA ploidy and clinical prognosis. None
of the patients with a normal DNA histogram or
d/ with an increased DNA tetraploid peak died as a
result of thyroid malignancy (mean follow-up 14.2
years, range 5-35 years). In contrast, 11 of 19
patients (58%) who demonstrated a DNA
aneuploid histogram subsequently died from
thyroid cancer. This was a significantly higher
incidence of cancer deaths (P<0.0005) than for
patients with tumours with normal or DNA tetra-
ploid histograms.
Primary tumour size has been identified as a
potentially important prognostic variable for
thyroid malignancies. For oncocytic thyroid
tumours, mean diameter of the normal pattern plus
,^. DNA tetraploid group tumours was 3.8+2.2cm
(range 0.5-10.0cm). The DNA aneuploid tumours
were significantly larger (P<0.05): mean diameter
5.4+2.6cm (range 2.0-11.0cm). However, tumour
diameter of patients that died from thyroid cancer
(mean 5.6+2.5cm, range 2.0-9.0cm) was not
statistically significantly larger than the tumour
diameters of survivors (mean 4.2+2.4cm, range
- 0.5-11.0cm).
Relative DNA content
Figure 3 Example of a typical DNA aneuploid
histogram.
tumour metastasis and two died as a result. None
of the patients with either a normal or a DNA
aneuploid histogram have shown evidence of
tumour progression.
Thyroid
All 37 (100%) paraffin-embedded tissue specimens
of predominantly oncocytic thyroid cancers
analyzed yielded high quality DNA histograms by
Discussion
Oncocytic tumours of the salivary glands, renal
parenchyma, and thyroid are relatively rare. Even
in a large institution, new patients with such
tumours appear very infrequently, as exemplified by
the extensive time period (1943-1983) required to
collect these tumour specimens at the Mayo Clinic.
However, with the method of extracting nuclei from
pathologic archival material described by Hedley et
al. (1983), retrospective DNA ploidy analysis of a
substantial number of these unusual tumours of the
salivary glands, kidney, and thyroid is now
possible.FLOW CYTOMETRY OF ONCOCYTIC TUMOURS 803
All the tumour specimens studied herein had
similar histologic appearances by light microscopy
when stained with haematoxylin and eosin. Never-
theless, flow cytometric analysis of nuclear DNA
clearly distinguished DNA ploidy variation among
these oncocytic tumours. All specimens of oncocytic
tumours of the salivary gland showed a normal
DNA histogram pattern, identical to non-tumour
tissues studied. Clinical follow-up of the patients
with salivary gland tumours showed no evidence of
tumour recurrence, metastasis, or death. In contrast
to the oncocytic salivary tumours, the oncocytic
renal tumours studied displayed a diverse variation
in nuclear DNA ploidy, with 40% showing a
substantial increase in the 4C DNA peak, and 15%
of tumours showing a distinct DNA aneuploid
peak. Three patients with tumours showing an
increased DNA tetraploid peak developed tumour
metastasis or death. Finally, the oncocytic thyroid
cancers exhibited yet another variation in nuclear
DNA patterns among the oncocytic tumours
studied. Fifty-one percent of oncocytic thyroid
cancers had an easily identifiable DNA aneuploid
peak; 58% of the patients with a DNA aneuploid
peak subsequently died from thyroid cancer.
Oncocytic thyroid cancers showing a normal or
DNA tetraploid pattern were not associated with
cancer deaths during a 5 to 35 year period of
clinical follow-up.
Bennington & Mayall (1983) have studied nine
cases of oncocytic renal tumours by static DNA
cytometry. Comparison of their data with the flow
cytometry data found herein is not readily per-
formed. Johanessen et al. (1981) and Kramer et al.
(1985) each studied two cases of oncocytic thyroid
tumours by flow cytometry. Comparison of the
results found in these two papers which used freshly
excised tumour cells with that found in the current
report also is not possible.
Normal DNA histograms were markers of
favourable clinical behaviour for all three tumour
types studied here. No ready explanation can be
offered for why the presence of a DNA aneuploid
peak had important negative prognostic significance
for oncocytic thyroid tumours but not for oncocytic
renal tumours. Similarly, we can offer no
explanation for why a DNA tetraploid pattern was
associated with malignant behaviour for three renal
oncocytic tumours, but was not associated with
tumour metastasis or death for oncocytic thyroid
tumours. However, the differences in nuclear DNA
patterns and tumour behaviour found for these two
tumour groups suggests that generalizations about
the prognostic importance of a particular DNA
ploidy pattern must be guarded even within a
group of histologically very similar tumours.
Rather, it appears that DNA ploidy patterns and
their relevance for tumour behaviour must be
separately evaluated for each specific organ site and
histologic pattern of tumour.
These data demonstrate that flow cytometry on
extracted nuclei from deparaffinized pathology
sample blocks (Hedley et al., 1983; 1985) allows a
systematic investigation of nuclear DNA ploidy
patterns in a group of rare oncocytic tumours. The
results show that nuclear DNA ploidy measure-
ments performed by flow cytometry on three
separate biologic classes of oncocytic tumours,
albeit with similar histologic appearances, can
provide useful new information relevant to
subsequent tumour behaviour and clinical
prognosis.
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